Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical ...
Plus Therapeutics, Inc. has announced the successful completion of the ReSPECT-LM Phase 1 trial, which evaluated the safety and efficacy of intrathecally administered Rhenium (186Re) Obisbemeda for ...
Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...
AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results